This announcement contains inside
information as stipulated under the UK version of the
Market Abuse Regulation No 596/2014 which is part of English law by
virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information
service, this information is considered to be in the public
domain.
26 June
2024
EDX
Medical Group plc
AQSE:
EDX
("EDX
Medical" or the "Company")
EXCLUSIVE COMMERCIAL
PARTNERSHIP FOR PIONEERING
CANCER DRUGS RESPONSE ASSAY
IN UK AND NORDICS
CAMBRIDGE, UK: EDX Medical
Group plc, which develops innovative digital diagnostic products and
services supporting personalised treatments for cancer, heart
disease and infectious diseases, announces
today it has signed an exclusive distribution agreement with
Curesponse Ltd ("Curesponse"), to market the
cResponse™ cancer assay in the UK, Sweden,
Finland, Norway and Denmark.
cResponse™ is a groundbreaking
platform that biologically assesses how an individual patient's
living tumour tissue responds to selected medicines, identifying
the most effective treatment options. It is the only clinical-grade
technology providing biological response data for chemotherapy,
targeted biologics, and immunotherapy drugs. This platform helps
clinicians rapidly pinpoint optimal treatments, potentially saving
lives, reducing treatment costs, and accelerating the discovery and
development cycles for pharmaceutical companies seeking new cancer
drugs.
The cResponse™ platform generates a
report ranking selected cancer drugs based on their predicted
effect on an individual patient's tumour, demonstrating over 90%
accuracy in clinical trials. The test can be augmented with rapid
genomic sequencing to identify additional drug candidates for
functional analysis. The entire process is powered by proprietary
technologies and advanced AI algorithms. The platform technology
has been refined and calibrated using thousands of cancer tissues,
demonstrating its clinical utility and effectiveness through
hundreds of cases in Israel and the UK. The cResponse™ test is
performed at a United Kingdom Accreditation
Service (UKAS) accredited lab in London and
has also earned a CE mark for Europe, underscoring its regulatory
approval and readiness for clinical use.
EDX Medical will initiate commercial
activities to support the clinical use of the
cResponse™ assay in the UK and Nordics with
immediate effect and will explore broadening the agreement with
Curesponse in due course.
Professor Sir Chris Evans, OBE, founder of EDX
Medical plc, commented: "We are delighted to be increasing
accessibility to this genuinely innovative and pioneering test
which potentially offers tremendous benefit to those treating
cancer and their patients. This product is an excellent addition to
our rapidly growing portfolio of class-leading diagnostic
solutions."
Dr Mike Hudson, CEO, EDX Medical plc, said: "We
are very pleased to have been selected by Curesponse as their
partner, and to be able to make their breakthrough assay available
for our clients in the UK and Nordics. We consider
cResponse™ to be an
outstanding innovation in the fast-moving clinical cancer
diagnostic landscape."
Guy Neev, CEO of Curesponse Ltd, commented: "We
are thrilled to partner with EDX Medical Group to bring our
cResponse™ platform to patients and clinicians in the UK and Nordic
countries. Our mission at Curesponse is to make this technology
available to cancer patients to optimize treatment outcomes and
save lives. This collaboration is a significant step toward
achieving that goal. We look forward to working closely with the
EDX Medical team to ensure the successful adoption and
implementation of this groundbreaking decision support
tool."
The Board of directors of EDX Medical plc
accepts responsibility for this announcement.
Contacts:
|
EDX
Medical plc
|
|
|
|
Dr Mike Hudson (Chief Executive
Officer)
|
+44
(0)7812 345 301
|
|
|
|
|
|
|
Oberon Capital
|
|
|
|
Nick Lovering (Corporate
Adviser)
Adam Pollock (Corporate
Broking)
Mike Seabrook (Corporate
Broking)
|
+44 (0)20
3179 5300
|
|
|
|
|
|
|
Media House International
|
|
|
|
Ramsay Smith
Gary McQueen
|
+44
(0)7788 414856
ramsay@mediahouse.co.uk
+ 44
(0)7834 694609
gary@mediahouse.co.uk
|
|
|
IFC Advisory
(Investor Relations)
Tim Metcalfe
Graham Herring
|
+44 (0) 203 934
6630
|
|
|
|
| |
Notes for
Editors:
About EDX Medical Group
The EDX Medical Group plc is listed
on the Apex Segment of the AQSE Growth Market (TIDM:
EDX).
EDX Medical was founded by
Professor Sir Christopher Evans, OBE, a medical and life
sciences entrepreneur with more than 30 years of experience,
together with CEO, Dr Mike Hudson.
By translating clinical insights
into pragmatic solutions combining advanced biological and digital
technologies, EDX Medical seeks to cost effectively improve the
detection and characterisation of disease in order to personalise
treatment in a timely fashion. Early disease detection and
biologically-based personal treatment optimisation is considered to
be the most impactful way of reducing deaths and lowering the cost
of healthcare globally.
EDX Medical Group provides doctors,
hospitals and insurers/payers with access to a portfolio of the
best clinical diagnostics products and services. The Company
operates its own facilities in Cambridge and Oxford, UK, and has
strategic product and technology partnerships with organisations
such as Thermo Fisher EMEA Ltd, a world leader in supplying life
sciences solutions and services.
EDX Medical conducts product
development, validation and distribution to ISO 13485 and provides
PCR and genomic sequencing services accredited to ISO 15189 by
the United Kingdom Accreditation
Service (UKAS).
www.edxmedical.com
About Curesponse
Ltd
Curesponse is a pioneering leader in
precision oncology. Founded on extensive research originating from
the esteemed Weizmann Institute of Science on the
Tumour-Micro-Environment, and supported by impactful publications,
Curesponse is transforming the landscape of cancer care and
oncology drug development.
The company has developed a Personal
Derived Explants (PDE) platform, with the ability to accurately
predict human responses to a diverse range of cancer therapies and
oncology drug candidates with an unprecedented accuracy rate. This
platform enables personalised matching with the most suitable drug
from the outset, maximizing the likelihood of a favourable
response, reducing unnecessary treatments, and generating cost
savings for healthcare systems.
The company operates accredited labs
in Israel and in the UK at the London Cancer Hub. and has
landmarked a CE mark for Europe and granted patents for EU and US,
in its expansion roadmap.
www.curesponse.com